Cancer Chemotherapy and Pharmacology

, Volume 83, Issue 5, pp 993–998 | Cite as

Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38

  • Mariko Iwase
  • Ken-ichi FujitaEmail author
  • Yuki Nishimura
  • Natsumi Seba
  • Yusuke Masuo
  • Hiroo Ishida
  • Yukio Kato
  • Yuji Kiuchi
Short Communication



Pazopanib is an orally active, multi-targeted tyrosine kinase inhibitor. A previous phase I study demonstrated that coadministration of pazopanib with irinotecan increases the area under the plasma concentration–time curve (AUC) for SN-38, an active metabolite of irinotecan. To clarify the possible mechanism underlying that drug–drug interaction, we investigated the potential for pazopanib to inhibit UDP-glucuronosyltransferase (UGT)1A1 and organic anion-transporting polypeptide (OATP)1B1, which are involved in detoxification and hepatic uptake of SN-38, respectively.


Human liver microsomes (HLMs) and recombinant human UGT1A1, and HEK293 cells stably transfected with OATP1B1 were used to evaluate the inhibitory effects of pazopanib against glucuronidation, and hepatic uptake of SN-38, respectively. Kinetic analysis was performed to estimate inhibition constants, which were corrected for non-specific binding to enzyme sources (Ki,u values).


Concentration-dependent inhibition of SN-38 glucuronidation was observed in the HLMs and recombinant human UGT1A1 experiments: Pazopanib noncompetitively inhibited SN-38 glucuronidation by HLMs (Ki,u = 1.6 ± 0.05 µM) and recombinant human UGT1A1 (Ki,u = 0.69 ± 0.02 µM). Pazopanib-induced increases in SN-38 AUC estimated using Ki,u values were comparable to those observed in patients of the phase I study who received both irinotecan and pazopanib. Such results suggest that the drug–drug interaction is at least partially mediated by inhibition of UGT1A1. In contrast, pazopanib did not inhibit OATP1B1-mediated SN-38 uptake at concentrations up to 60 µM.


Results showed that pazopanib inhibits UGT1A1-mediated SN-38 glucuronidation, but not OATP1B1-mediated SN-38 uptake.


Pazopanib UGT1A1 SN-38 Pharmacokinetics Drug–drug interaction 



This study was supported in part by a Grant-in-Aid for Scientific Research (C) [16K08918 to H.I.] from the Japan Society for the Promotion of Science (JSPS).

Compliance with ethical standards

Conflict of interest

We have no conflict of interest to declare.

Ethical standards

No human and/or animal studies were performed in this study.


  1. 1.
    Miyamoto S, Kakutani S, Sato Y, Hanashi A, Kinoshita Y, Ishikawa A (2018) Drug review: pazopanib. Jpn J Clin Oncol 48:503–513CrossRefGoogle Scholar
  2. 2.
    Spigel DR, Burris HA 3rd, Greco FA, Shih KC, Gian VG, Lipman AJ, Daniel DB, Waterhouse DM, Finney L, Heymach JV, Hainsworth JD (2018) Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: a randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures. Cancer 124:2355–2364CrossRefGoogle Scholar
  3. 3.
    Bennouna J, Deslandres M, Senellart H, de Labareyre C, Ruiz-Soto R, Wixon C, Botbyl J, Suttle AB, Delord JP (2015) A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer. Investig New Drugs 33:138–147CrossRefGoogle Scholar
  4. 4.
    Dembla V, Groisberg R, Hess K, Fu S, Wheler J, Hong DS, Janku F, Zinner R, Piha-Paul SA, Ravi V, Benjamin RS, Patel S, Somaiah N, Herzog CE, Karp DD, Roszik J, Meric-Bernstam F, Subbiah V (2017) Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Sci Rep 7:15963CrossRefGoogle Scholar
  5. 5.
    Fruehauf JP, El-Masry M, Osann K, Parmakhtiar B, Yamamoto M, Jakowatz JG (2018) Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma. Cancer Chemother Pharmacol 82:353–360CrossRefGoogle Scholar
  6. 6.
    Fujita K, Sasaki Y (2014) Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the ‘real world’. Drug Metab Pharmacokinet 29:20–28CrossRefGoogle Scholar
  7. 7.
    Fujita K, Sugiura T, Okumura H, Umeda S, Nakamichi N, Watanabe Y, Suzuki H, Sunakawa Y, Shimada K, Kawara K, Sasaki Y, Kato Y (2014) Direct inhibition and down-regulation by uremic plasma components of hepatic uptake transporter for SN-38, an active metabolite of irinotecan, in humans. Pharm Res 31:204–215CrossRefGoogle Scholar
  8. 8.
    Xu CF, Reck BH, Xue Z, Huang L, Baker KL, Chen M, Chen EP, Ellens HE, Mooser VE, Cardon LR, Spraggs CF, Pandite L (2010) Pazopanib-induced hyperbilirubinemia is associated with Gilbert’s syndrome UGT1A1 polymorphism. Br J Cancer 102:1371–1377CrossRefGoogle Scholar
  9. 9.
    Khurana V, Minocha M, Pal D, Mitra AK (2014) Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors. Drug Metabol Drug Interact 29:249–259Google Scholar
  10. 10.
    Hamberg P, Mathijssen RH, de Bruijn P, Leonowens C, van der Biessen D, Eskens FA, Sleijfer S, Verweij J, de Jonge MJ (2015) Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules. Cancer Chemother Pharmacol 75:365–371CrossRefGoogle Scholar
  11. 11.
    Fujita K, Sugiyama M, Akiyama Y, Ando Y, Sasaki Y (2011) The small-molecule tyrosine kinase inhibitor nilotinib is a potent noncompetitive inhibitor of the SN-38 glucuronidation by human UGT1A1. Cancer Chemother Pharmacol 67:237–241CrossRefGoogle Scholar
  12. 12.
    Burns K, Nair PC, Rowland A, Mackenzie PI, Knights KM, Miners JO (2015) The nonspecific binding of tyrosine kinase inhibitors to human liver microsomes. Drug Metab Dispos 43:1934–1937CrossRefGoogle Scholar
  13. 13.
    Miners JO, Chau N, Rowland A, Burns K, McKinnon RA, Mackenzie PI, Tucker GT, Knights KM, Kichenadasse G (2017) Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: implications for hyperbilirubinemia. Biochem Pharmacol 129:85–95CrossRefGoogle Scholar
  14. 14.
    Fujita K, Masuo Y, Okumura H, Watanabe Y, Suzuki H, Sunakawa Y, Shimada K, Kawara K, Akiyama Y, Kitamura M, Kunishima M, Sasaki Y, Kato Y (2016) Increased plasma concentrations of unbound SN-38, the active metabolite of irinotecan, in cancer patients with severe renal failure. Pharm Res 33:269–282CrossRefGoogle Scholar
  15. 15.
    de Jong FA, Kitzen JJ, de Bruijn P, Verweij J, Loos WJ (2006) Hepatic transport, metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain. Cancer Biol Ther 5:1105–1110CrossRefGoogle Scholar
  16. 16.
    Ito K, Hallifax D, Obach RS, Houston JB (2005) Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab Dispos 33:837–844CrossRefGoogle Scholar
  17. 17.
    Yu H, van Erp N, Bins S, Mathijssen RH, Schellens JH, Beijnen JH, Steeghs N, Huitema AD (2017) Development of a pharmacokinetic model to describe the complex pharmacokinetics of pazopanib in cancer patients. Clin Pharmacokinet 56:293–303CrossRefGoogle Scholar
  18. 18.
    Keisner SV, Shah SR (2011) Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs 71:443–454Google Scholar
  19. 19.
    Imbs DC, Négrier S, Cassier P, Hollebecque A, Varga A, Blanc E, Lafont T, Escudier B, Soria JC, Pérol D, Chatelut E (2014) Pharmacokinetics of pazopanib administered in combination with bevacizumab. Cancer Chemother Pharmacol 73:1189–1196CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Mariko Iwase
    • 1
  • Ken-ichi Fujita
    • 2
    • 3
    Email author
  • Yuki Nishimura
    • 1
  • Natsumi Seba
    • 4
  • Yusuke Masuo
    • 4
  • Hiroo Ishida
    • 5
  • Yukio Kato
    • 4
  • Yuji Kiuchi
    • 1
  1. 1.Department of PharmacologyShowa University School of MedicineTokyoJapan
  2. 2.Institute of Molecular OncologyShowa UniversityTokyoJapan
  3. 3.Division of Cancer Cell Biology, Department of Pharmaceutical ScienceShowa University School of PharmacyTokyoJapan
  4. 4.Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health SciencesKanazawa UniversityKanazawaJapan
  5. 5.Division of Medical Oncology, Department of MedicineShowa University School of MedicineTokyoJapan

Personalised recommendations